New Brunswick Becomes Third Province in Canada to Implement Biosimilar Switching Policy
News provided by
Share this article
Share this article
TORONTO, April 21, 2021 /CNW/ - Biosimilars Canada, a national association representing Canada s biosimilar medicines industry, today congratulated the Government of New Brunswick for implementing a biosimilar switching or transitioning policy to expand the use of biosimilar medicines under the province s public drug plans.
New Brunswick s new biosimilar policy is expected to save the province more than $10 million annually when fully implemented, which will be reinvested to support coverage of new therapies. About 3,000 patients on the province s drug plans who are living with diseases such as arthritis, diabetes, inflammatory bowel disease and psoriasis will have until November 30 to switch from an originator biologic drug to a biosimilar biologic drug.
Canada
United-kingdom
Toronto
Ontario
British
Canadian
Dorothy-shephard
Jim-keon
Michel-robidoux
Jeff-connell
Alberta-health
Health-canada